GUANGZHOU, China, Jan. 17, 2025 /PRNewswire/ -- Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited (HKEX: 2096) have announced a partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4. FZ002-037 is a highly selective oral...
Read More Details
Finally We wish PressBee provided you with enough information of ( Fermion and Simcere Enter into an Exclusive License and Collaboration Agreement for China's First SSTR4 Agonist Targeting Pain )
Also on site :
- Country Hitmaker Brings Out Unexpected Guest in 'Dream Collab' Moment
- Bianca Censori Wears Edible Lingerie in Public With Kanye West
- Starmer will slash firms’ energy bills amid warnings net zero costs are crippling British industry